Physician profile
Naeem Aftab
NPI 1679668719
$9,077.46
in general payments reported to CMS, 2019-2025
16 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $243 · 2021: $1,793 · 2022: $2,343 · 2023: $2,194 · 2024: $1,278 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,627 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,626.97 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,858.04 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $1,457.83 | 2021-2025 | Invega Trinza, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $1,353.56 | 2020-2025 | Uzedy, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,177.43 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,168.33 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $575.77 | 2023-2025 | Auvelity |
| Alkermes, INC. | $494.38 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $212.37 | 2022-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $126.62 | 2025 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $115.04 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.34 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $100.00 | 2022 | |
| Eisai INC. | $98.35 | 2021 | |
| Sunovion Pharmaceuticals INC. | $89.52 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $18.88 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeem Aftab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.